NRXP NRX Pharmaceuticals, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
14:43
Jan 06
Jan 06
Cash-poor balance sheet likely forces further dilutive financing.
NRx Pharmaceuticals has about $7m cash and $30.6m debt/payables due this year and no way to pay beyond dilution. It already diluted investors to pay down debt and still has a very large current-liability balance. The author expects further dilution within 6-12 months and doubts it will keep the company afloat.
HIGH
13:46
Jan 02
Jan 02
Avoid NRXP on weak cash and heavy debt due.
Author warns NRXP has only $7m cash against $41 million debt/payables due this year and no way to pay beyond dilution. This impending bankruptcy alert makes the shares unattractive; the main stated risk is forced dilution.
HIGH
About NRXP Investor Commentary
Across the available history and selected sources, Buzzberg tracks NRXP (NRX Pharmaceuticals, Inc.) across 1 sources: 0 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: u/No_Cell6708.